Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
think today 1 $ is done easily......yesterday people didn't know enough about the merger..today many they will be very bullish...
this share can erupt at any time...Albireo is a very potent and respected partner..see links below
Albireo has an excellent reputation and many successes also in phase III studies ..
"Albireo’s pipeline and coupled with Biodel’s cash resources, will enable the combined company to reach significant milestones.”
"Albireo’s pipeline and coupled with Biodel’s cash resources, will enable the combined company to reach significant milestones.”
!! Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals
http://www.albireopharma.com/2016/05/24/biodel-inc-and-albireo-limited-agree-to-combine/
..have taken the chance and bought another 20,000 ..it's wow today..
no chance for bears...lol
..what's that supposed to be..DOUBLE-SQUEEZE ??
such a share I never had...incomprehensible
!!! that's incredible the stock flying to mars
premarket $ .29 (06:35:16 )
What Analysts Say about this Stock:
The Company has received rating from WSJ analysts. Currently the stock has been rated as “Buy” from 5 Analysts. 1 Analyst has suggested “Sell” for the company. 18 Analysts have rated the company as a “Hold”.
http://www.streetupdates.com/2016/05/20/analysts-stocks-rating-activity-xg-technology-inc-nasdaqxgti-brocade-communications-systems-inc-nasdaqbrcd/
"What we like about XGTI is that the company has a strong IP portfolio. xG has a broad portfolio of intellectual property that enables always-available, always-connected and always-secure voice, broadband data and video communications. xG is the developer of xMax, a patented all-IP software-defined cognitive radio network that delivers mission-assured wireless connectivity in any RF environment
Currently trading with a market cap of $5.1 million, XGTI has has over 100 patents and pending patent applications. The company has some great technology and patents. Management just needs to monetize XGTI’s assets and deliver."
http://www.insiderfinancial.com/xg-technology-inc-nasdaqxgti-making-a-comeback/115574/
We expect our research and development costs to continue to decrease going forward as we implemented additional cost saving measures in April 2016 which included a further reduction in our current full-time, part-time and contracted workforce.
In 2015, we implemented cost reduction initiatives that included a decrease in our current full, part-time and contracted workforce. These initiatives resulted in a reduction in monthly operating expenses to approximately $800,000 - an improvement of over 30%. This saved us approximately $3,500,000 in 2015.
http://www.marketwatch.com/story/10-q-xg-technology-inc-2016-05-23
Roger Branton, CFO of xG Technology, said, "We are pleased to note that xG realized record quarterly revenue in Q1 2016, of which two months of revenue is attributable to IMT as the acquisition closed on January 29, 2016. We expect the strong revenue achieved in Q1 to continue in the Q2 period.
The cost reduction initiatives we began during Q1 2016 (which were announced after the close of the quarter) have further reduced xG's overall monthly operating expenses to approximately $500,000 on the xMax brand. This has strengthened xG's financial foundation and ability to profitably pursue new business opportunities and initiatives going forward."
=> concusion ER isn't so bad...
@ moe money ..please tell me, why BBEP delisting will not happen-where did you get this information?
BBEP is poised for a big move! Noone knows if the common will be wiped out. Many of these Chapter 11 work out. take UPLMQ, after announcement down to .16, two weeks later .85??
agree price target today 0,25 $..IMO
CLRB completed a $7.2 million capital raise after the first quarter ended, so the company is well funded going forward.
Cellectar Biosciences Inc (NASDAQ:CLRB) Rockets Higher.
We think the patent news is the first of many more positive news announcements to come from the company. We think the worst is behind the company and a bull run is just getting started.
source: http://www.insiderfinancial.com/cellectar-biosciences-inc-nasdaqclrb-rockets-higher/115593/
Large swings to the up side for the next few days to the upside. stable financials, signif product line & now a patent many need!
Insiders bought as well. I don't understand how people can be Bearish? Based on the volume alone and the fact it held at the end of the day, its going higher..
..where are the gaps? first about 2$ and second about 12 $
I can see the squeeze already...)
EBIO Get Ready for the run today!!
We break the $1.5 and we are clear into the $2's
EBIO oversold - enormous upside potential
•Maximizing shareholder value is its goal.
http://www.google.com/finance?q=ebio&ei=1Rs7V_ndJ8qCsAGN1YzYCA
Price target 3,50 $ or even more ?
Buyout Likely Coming & SQUEEZE => BOOM
EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) Average Rating Recap
Todd Miller?May 11, 2016
Biopharmaceuticals, Inc. (NASDAQ:EPRS) have a current average rating of 4. This specific rating uses a scale from 1 to 5. Following this scale, a rating of 5 would indicate a Strong Buy recommendation. A rating of 1 would signify a Strong Sell. Out of the 3 total compiled ratings, 3 have given the stock a Moderate Buy rating, and 0 have marked the stock as a Strong Buy.
Currently, sell-side analysts providing data compiled by Zacks Research have set a consensus target price of $12 on the stock. These target prices presently range from 10 to $15. These same analysts have also offered ratings on the stock.
http://www.bibeypost.com/epirus-biopharmaceuticals-inc-nasdaqeprs-average-rating-recap/
Epirus Biopharmaceuticals stock price target cut to $2 from $11 at Wedbush Securities
http://www.finanzen.net/nachricht/aktien/Epirus-Biopharmaceuticals-stock-price-target-cut-to-2-from-11-at-Wedbush-Securities-4877958
Epirus Biopharmaceuticals stock price target cut to $2 from $11 at Wedbush Securities
http://www.finanzen.net/nachricht/aktien/Epirus-Biopharmaceuticals-stock-price-target-cut-to-2-from-11-at-Wedbush-Securities-4877958
Epirus Biopharmaceuticals stock price target cut to $2 from $11 at Wedbush Securities
http://www.finanzen.net/nachricht/aktien/Epirus-Biopharmaceuticals-stock-price-target-cut-to-2-from-11-at-Wedbush-Securities-4877958
Epirus Biopharmaceuticals stock price target cut to $2 from $11 at Wedbush Securities
http://www.finanzen.net/nachricht/aktien/Epirus-Biopharmaceuticals-stock-price-target-cut-to-2-from-11-at-Wedbush-Securities-4877958
Hot Research
New Epirus Model Sacrifices Clarity
May 12, 2016 3:36 a.m. ET
First price target 2 $
http://www.barrons.com/articles/new-epirus-model-sacrifices-clarity-1463038583?mod=yahoobarrons&ru=yahoo
new price target after contract with AT&T...
The mean price target for the shares of Synergy Resources Corporation (SYRG) is at 9.32 while the highest price target suggested by the analysts is 12.00 and low price target is 7.00. The mean price target is calculated keeping in view the consensus of 20 brokerage firms.
Impact on financials
Synacor Inc. (NASDAQ: SYNC) originally guided 2016 revenue at $125 million, but with the AT&T contract, the company has set itself on the trajectory to hit $225 million in revenue this year. The AT&T deal is also expected to give a major boost Synacor’s bottom-line after it puts the right systems in place. In the case of Yahoo, the bulk of the $100 million contract flowed directly to the bottom-line because supporting AT&T’s Web and mobile services carried a lower cost structure.
http://scibilitymedia.com/synacor-inc-nasdaqsync-displaces-yahoo-yhoo-lucrative-att-contract/
AT&T Leaves Yahoo! For Synacor
http://www.quotenet.com/news/stocks/AT&T-Leaves-Yahoo!-For-Synacor-1001189894
this is not some biotech pump and dump. This is legit and big boys will take notice in comming days and weeks
deal with AT&T is a company builder. Upside should continue on Monday. Friday was a consolidation period. Bullish
Synacor has tremendous potential ahead - STRONG BUY
MO - Synacor-Aktie: "outperform"
14:22 02.05.16